Enterprise war epidemic: 120 of 182 pharmaceutical companies achieve growth

Enterprise war “epidemic”: 120 of 182 pharmaceutical companies achieve growth

For stocks, please read Jin Qilin analyst research report, authoritative, professional, timely, and comprehensive, to help you tap potential potential opportunities!

  Original title: 182 pharmaceutical companies, 120 realized growth!

  Recently, listed pharmaceutical companies that have performed well in the “epidemic” have released quick performance reports, and 80% of pharmaceutical companies have achieved growth. Among them, medical equipment and Chinese medicine companies have a stable growth momentum.

  Reviewing the performance forecast, 182 listed companies in the pharmaceutical industry announced on schedule, and 120 companies realized growth; from the perspective of net profit and growth increase, 37 companies are expected to achieve doubling growth.

  Medical devices: market development drives sales growth. As a leading domestic supplier of nucleic acid molecule detection, Capo Biotech is rushing to the forefront of the “epidemic” instead of delivering a satisfactory performance report as scheduled.

  Capo Biotech released a performance report on February 20th, which combined the report. The company’s operations are stable, its financial position is good, and its operating income is 7.

USD 3.6 billion, a year-on-year increase of 26.

76%; realized net profit attributable to shareholders of the listed company is 1.

4.9 billion yuan, an increase of 30 over the same period last year.

24%, net profit attributable to shareholders of listed companies after excluding non-recurring gains and losses.

400 million, an increase of 41 every year.

14%.

  According to the company’s weighing, the performance growth is based on the company’s annual business plan and long-term development strategy. The company’s work has been carried out in an orderly manner. HPV’s operating income has maintained steady growth, and the gap between the increase in income of new products such as the poor, deaf and STD has increased.Fast growth.

  In the year of 2019, the company achieved operating income of 14.

USD 3.2 billion, an increase of 40 over the same period last year.

86%; net profit attributable to shareholders of listed companies5.

700 million yuan, an increase of 41 over the same period last year.

90%; net profit after deductions increased by 48 over the same period last year.

26%.

  As a leading company in the field of hemoperfusion, the company’s performance in the fields of uremia, liver disease and dialysis powder has become the biggest highlight of the company’s performance growth.

  In the field of uremia, through academic promotion, the company increased sales staff expenses and continuously increased the sales revenue of each hospital.

In 2019, the company’s HA130 blood perfusion device sales 四川耍耍网 revenue was approximately 9.

68ppm, an increase of 46 per year.

45%.

  In the field of liver disease, the company’s main liver disease product BS330 blood perfusion device sales revenue is about 7328.

210,000 yuan, an annual increase of 63.

65%.

At the same time, the company’s liver disease sales team sank to the “one city, one center” project hospital to expand DPMAS technology. The report pointed out that the 138 “one city, one center” hospital’s BS330 blood perfusion device sales revenue was about 3657.

460,000 yuan, an annual increase of about 114.

69%.

  In the field of dialysis powder, the company has expanded the company’s product system by upgrading product quality, rebuilding the sales system, and improving service quality.

During the reporting period, the company’s sales of kidney powder products were 2,204.

0.6 million yuan, an annual increase of 54.

29%.

  Base Egg Bio Base Egg Bio’s main business is POCT in vitro diagnostic reagents and supporting instruments. Thanks to the increase in market development in 2019, the company’s business has continued to grow steadily, while strengthening internal operating cost control management, which has further improved the company’s overall profit.

  The company’s operating income in 2019 was 9.

7.1 billion yuan, an increase of 41 over the same period last year.

44%; realized net profit of 3.3.8 billion, an increase of 35 over the same period last year.

58%; The company achieved growth in basic earnings in 20191.

30 yuan, an increase of 35 over the same period last year.

08%.

  Traditional Chinese medicine: the core product is built to increase the use rate of “good recipes” in the treatment of new coronary pneumonia by more than 80%, and the combat effectiveness of Chinese medicine companies in fighting the epidemic has been widely recognized by the market.

Recently, a large number of Chinese medicine companies have released their performance reports as scheduled, and what “healthy recipes” behind stable growth have attracted market attention.

  The so-called “things are rare and expensive” in Pianzai, the company replaces Tsai in the hands of valuables, the company continues to grow without worry.

Pianzai recently released the 2019 performance report, and the company achieved a total operating income of 57.

4.5 billion, an annual increase of 20.

54%; Net profit attributable to shareholders of listed companies.

$ 7.4 billion, an increase of 20 per year.

twenty four%.

  The company stated that the growth in performance was mainly due to the company’s core product Pien Tze Huang series products, the subsidiary Fujian Pien Tze Huang Cosmetics Co., Ltd. (merger) and Zhangzhou Pian Tsai Feng Shanghai Jiahua Oral Care Co., Ltd. sales growth.

  After the close on the 20th, the company issued a favorable price increase.

  According to the announcement, considering the main raw materials and labor costs of Pien Tze Huang products, the company decided to introduce the product Pien Tze Huang Tablets from the date of the announcement. The domestic market retail price was reset by 530 yuan / capsule and raised to 590 yuan / cap.Increase by about 40 yuan / capsule; supply prices in overseas markets will increase by about 5.

$ 80 per capsule.

  Qianjin Pharmaceutical leverages the “Qianjin” brand’s leading position in the domestic gynecological medicine field. The company has established exclusive Chinese medicine protection varieties such as gynecological Qianjin tablets (capsules) and Buxueyimu pills (granules) for stable sales.

  In 2019, Qianjin Pharmaceutical achieved total operating income.

25ppm, maintaining steady growth; achieving a net profit of 2.

9.4 billion, an annual increase of 15.

20%.

  Qizheng Tibetan Medicine Company develops traditional Tibetan medicine through modern scientific and technological innovation. The main drugs currently produced include major pain relief plasters, Qingpeng ointment, Baimai ointment and other external products, as well as oral Tibetan medicine products such as Honghua Ruyi Pill.
Benefiting from the steady growth of the above-mentioned drugs, the company’s pharmaceutical business will increase by 15 year-on-year in 2019.

75%.

  According to the performance express report, the company achieved operating income of 1.4 billion US dollars, an annual growth rate of 15.

62%; realized net profit3.

6.4 billion, an annual increase of 14.

27%.